Low- Dose hypofractionated total skin electron beam therapy in mycosis fungoides—a single institutional experience

Hussein, Amr; Elsheredy, Heba

doi:10.21608/zumj.2022.162823.2644

Low- Dose hypofractionated total skin electron beam therapy in mycosis fungoides—a single institutional experience

Document Type : Original Article

Authors

Amr Hussein ¹
Heba Elsheredy ²

¹ Cancer Management and Research Department, Medical Research Institute, Alexandria University, Alexandria, Egypt

² Heba G. El-Sheredy, Cancer Management and Research Department, Medical Research Institute, Alexandria University. Alexandria,Egypt

10.21608/zumj.2022.162823.2644

Abstract

Background: Mycosis fungoides (MF) is the most common type of cutaneous T-cell lymphoma and is usually has an indolent course with slowly progressive lesions. Total skin electron beam therapy (TSEBT) is considered the most effective skin-directed treatment for MF. TSEBT as a single modality can provide adequate disease control without major cumulative toxicities. Cd-TSEBT of 30–36 Gy achieves a high overall response with acceptable toxicity. The impact of lowering the total TSEBT dose and shorten the overall treatment course has been investigated with a satisfactory clinical response and reduction of radiation-related toxicities. Aim: We conducted a single-institutional study to evaluate disease response, and toxicity using a low-dose hypofractionated course of TSEBT in patients with MF Methods: This prospective study included 17 patients with a histologically confirmed diagnosis of MF stage Ib to III illness, had failed at least one prior therapy, treated at Ayady Almostakbal Hospital, Alexandria, Egypt. The patients treated with hypofractinated TSET using 2.5 Gy over 10 fractions twice weekly to total does of 25 Gy. Results: The overall response rate was 94.1% where 64.7% complete response rate, 29.4% partial response rate and one patient lost follow up without completing course of radiotherapy. Erythema and fatigue were the most common treatment-related adverse events. The adverse events were nearly equally distributed between grade 1 and 2 toxicities. Conclusion: Low-dose hypofractionated TSBET provides a good treatment modality for patients with MF with a satisfactory response rate and an acceptable toxicity profile.

Keywords

Main Subjects